Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide
Hepatitis C Market Overview
Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.
Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.
A. Hepatitis C Drugs Market & Forecast (Chapter 2)
B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
C. Hepatitis C Deals & Acquisitions (Chapter 4)
D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)
1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
7. BI-207127 (Company: Boerhinger Ingelheim)
8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
9. ABT-267 (Company: Abbott Laboratories)
10. ABT-072/333 (Company: Abbott Laboratories)
11. Alisporivir (Company: Novartis)
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)
1. Mericitabine (RG-7128) (Company: Roche)
2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
3. GS-9256 (Company: Gilead Sciences)
4. GS-9451 (Company: Gilead Sciences)
5. MK-5172 (Company: Merck)
6. Sovaprevir (ACH-1625) (Company: Achillion)
7. IDX-320 (Company: Idenix)
8. MK-8742 (Company: Merck)
9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
10. IDX-719 (Company: Idenix)
11. PPI-668 (Company: Presidio Pharmaceuticals)
12. Setrobuvir (ANA-598) (Company: Roche)
13. VX-222 (Company: Vertex Pharmaceuticals)
14. GS-9669 (Company: Gilead Sciences)
15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)
16. BMS-791325 (Company: Bristol-Myers Squibb)
Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
1. Simeprevir (TMC 435)
2. Faldaprevir (BI 201335) (Boerhinger Ingelheim)
3. Asunaprevir (BMS-650032)
4. Sofosbuvir (PSI-7977 or GS-7977)
5. Daclatasvir (BMS-790052)
6. ABT-450/r (Ritonavir)
7. ABT-072/333
8. Alisporivir
9. Mericitabine (RG-7128)
10. Danoprevir (RG7227)
11. GS-9256
12. Setrobuvir (ANA-598)
13. VX-222
14. GS-9190 (Tegobuvir)
15. BMS-791325
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.
Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.
A. Hepatitis C Drugs Market & Forecast (Chapter 2)
B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
C. Hepatitis C Deals & Acquisitions (Chapter 4)
D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)
1. Pegasys
2. Pegintron
3. Incivek
4. Victrelis
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)
1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
7. BI-207127 (Company: Boerhinger Ingelheim)
8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
9. ABT-267 (Company: Abbott Laboratories)
10. ABT-072/333 (Company: Abbott Laboratories)
11. Alisporivir (Company: Novartis)
Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)
1. Mericitabine (RG-7128) (Company: Roche)
2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
3. GS-9256 (Company: Gilead Sciences)
4. GS-9451 (Company: Gilead Sciences)
5. MK-5172 (Company: Merck)
6. Sovaprevir (ACH-1625) (Company: Achillion)
7. IDX-320 (Company: Idenix)
8. MK-8742 (Company: Merck)
9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
10. IDX-719 (Company: Idenix)
11. PPI-668 (Company: Presidio Pharmaceuticals)
12. Setrobuvir (ANA-598) (Company: Roche)
13. VX-222 (Company: Vertex Pharmaceuticals)
14. GS-9669 (Company: Gilead Sciences)
15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)
16. BMS-791325 (Company: Bristol-Myers Squibb)
Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)
1. Simeprevir (TMC 435)
2. Faldaprevir (BI 201335) (Boerhinger Ingelheim)
3. Asunaprevir (BMS-650032)
4. Sofosbuvir (PSI-7977 or GS-7977)
5. Daclatasvir (BMS-790052)
6. ABT-450/r (Ritonavir)
7. ABT-072/333
8. Alisporivir
9. Mericitabine (RG-7128)
10. Danoprevir (RG7227)
11. GS-9256
12. Setrobuvir (ANA-598)
13. VX-222
14. GS-9190 (Tegobuvir)
15. BMS-791325
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
1. EXECUTIVE SUMMARY
2. HEPATITIS C DRUGS – MARKET & FORECAST
3. HEPATITIS C – APPROVED DRUGS SALES & FORECAST
3.1 Pegasys Sales and Forecast
3.2 Pegintron Sales and Forecast
3.3 Incivek Sales and Forecast
3.4 Victrelis Sales and Forecast
4. HEPATITIS C – DEALS & ACQUISITIONS
5. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE III)
5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
5.4.1 Phase II
5.4.2 Phase III
5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
5.5.1 Phase II
5.5.2 Phase III
5.6 BI-207127 (Company: Boerhinger Ingelheim)
5.6.1 Phase I
5.6.2 Phase II
5.6.3 Phase III
5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5.7.1 Phase I
5.7.2 Phase III
5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
5.8.1 Phase I
5.8.2 Phase II
5.8.3 Phase III
5.9 ABT-267 (Company: Abbott Laboratories)
5.9.1 Phase II
5.9.2 Phase III
5.10 ABT-072/333 (Company: Abbott Laboratories)
5.10.1 Phase I
5.10.2 Phase II
5.10.3 Phase III
5.11 Alisporivir (Company: Novartis)
5.11.1 Phase II
5.11.2 Phase III
6. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE II)
6.1 Mericitabine (RG-7128) (Company: Roche)
6.1.1 Phase II
6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
6.2.1 Phase I
6.2.2 Phase II
6.3 GS-9256 (Company: Gilead Sciences)
6.3.1 Phase II
6.4 GS-9451 (Company: Gilead Sciences)
6.4.1 Phase II
6.5 MK-5172 (Company: Merck)
6.5.1 Phase I
6.5.2 Phase II
6.6 Sovaprevir (ACH-1625) (Company: Achillion)
6.6.1 Phase II
6.7 IDX-320 (Company: Idenix)
6.7.1 Phase I
6.8 MK-8742 (Company: Merck)
6.8.1 Phase I
6.8.2 Phase II
6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
6.9.1 Phase I
6.9.2 Phase II
6.10 IDX-719 (Company: Idenix)
6.10.1 Phase I
6.10.2 Phase II
6.11 PPI-668 (Company: Presidio Pharmaceuticals)
6.11.1 Phase I
6.12 Setrobuvir (ANA-598) (Company: Roche)
6.12.1 Phase I
6.12.2 Phase II
6.13 VX-222 (Company: Vertex Pharmaceuticals)
6.13.1 Phase I
6.13.2 Phase II
6.14 GS-9669 (Company: Gilead Sciences )
6.14.1 Phase I
6.14.2 Phase II
6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences)
6.15.1 Phase II
6.16 BMS-791325 (Company: Bristol-Myers Squibb)
6.16.1 Phase II
7. HEPATITIS C - PIPELINE DRUGS SALES FORECAST
7.1 Simeprevir (TMC 435) Sales Forecast
7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast
7.3 Asunaprevir (BMS-650032) Sales Forecast
7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast
7.5 Daclatasvir (BMS-790052) Sales Forecast
7.6 ABT-450/r (Ritonavir) Sales Forecast
7.7 ABT-072/333 Sales Forecast
7.8 Alisporivir Sales Forecast
7.9 Mericitabine (RG-7128) Sales Forecast
7.10 Danoprevir (RG7227) Sales Forecast
7.11 GS-9256 Sales Forecast
7.12 Setrobuvir (ANA-598) Sales Forecast
7.13 VX-222 Sales Forecast
7.14 GS-9190 (Tegobuvir) Sales Forecast
7.15 BMS-791325 Sales Forecast
2. HEPATITIS C DRUGS – MARKET & FORECAST
3. HEPATITIS C – APPROVED DRUGS SALES & FORECAST
3.1 Pegasys Sales and Forecast
3.2 Pegintron Sales and Forecast
3.3 Incivek Sales and Forecast
3.4 Victrelis Sales and Forecast
4. HEPATITIS C – DEALS & ACQUISITIONS
5. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE III)
5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.2 Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)
5.2.1 Phase I
5.2.2 Phase II
5.2.3 Phase III
5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
5.3.1 Phase I
5.3.2 Phase II
5.3.3 Phase III
5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
5.4.1 Phase II
5.4.2 Phase III
5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
5.5.1 Phase II
5.5.2 Phase III
5.6 BI-207127 (Company: Boerhinger Ingelheim)
5.6.1 Phase I
5.6.2 Phase II
5.6.3 Phase III
5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
5.7.1 Phase I
5.7.2 Phase III
5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
5.8.1 Phase I
5.8.2 Phase II
5.8.3 Phase III
5.9 ABT-267 (Company: Abbott Laboratories)
5.9.1 Phase II
5.9.2 Phase III
5.10 ABT-072/333 (Company: Abbott Laboratories)
5.10.1 Phase I
5.10.2 Phase II
5.10.3 Phase III
5.11 Alisporivir (Company: Novartis)
5.11.1 Phase II
5.11.2 Phase III
6. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE II)
6.1 Mericitabine (RG-7128) (Company: Roche)
6.1.1 Phase II
6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
6.2.1 Phase I
6.2.2 Phase II
6.3 GS-9256 (Company: Gilead Sciences)
6.3.1 Phase II
6.4 GS-9451 (Company: Gilead Sciences)
6.4.1 Phase II
6.5 MK-5172 (Company: Merck)
6.5.1 Phase I
6.5.2 Phase II
6.6 Sovaprevir (ACH-1625) (Company: Achillion)
6.6.1 Phase II
6.7 IDX-320 (Company: Idenix)
6.7.1 Phase I
6.8 MK-8742 (Company: Merck)
6.8.1 Phase I
6.8.2 Phase II
6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
6.9.1 Phase I
6.9.2 Phase II
6.10 IDX-719 (Company: Idenix)
6.10.1 Phase I
6.10.2 Phase II
6.11 PPI-668 (Company: Presidio Pharmaceuticals)
6.11.1 Phase I
6.12 Setrobuvir (ANA-598) (Company: Roche)
6.12.1 Phase I
6.12.2 Phase II
6.13 VX-222 (Company: Vertex Pharmaceuticals)
6.13.1 Phase I
6.13.2 Phase II
6.14 GS-9669 (Company: Gilead Sciences )
6.14.1 Phase I
6.14.2 Phase II
6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences)
6.15.1 Phase II
6.16 BMS-791325 (Company: Bristol-Myers Squibb)
6.16.1 Phase II
7. HEPATITIS C - PIPELINE DRUGS SALES FORECAST
7.1 Simeprevir (TMC 435) Sales Forecast
7.2 Faldaprevir (BI 201335) (Boerhinger Ingelheim) Sales Forecast
7.3 Asunaprevir (BMS-650032) Sales Forecast
7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast
7.5 Daclatasvir (BMS-790052) Sales Forecast
7.6 ABT-450/r (Ritonavir) Sales Forecast
7.7 ABT-072/333 Sales Forecast
7.8 Alisporivir Sales Forecast
7.9 Mericitabine (RG-7128) Sales Forecast
7.10 Danoprevir (RG7227) Sales Forecast
7.11 GS-9256 Sales Forecast
7.12 Setrobuvir (ANA-598) Sales Forecast
7.13 VX-222 Sales Forecast
7.14 GS-9190 (Tegobuvir) Sales Forecast
7.15 BMS-791325 Sales Forecast
LIST OF FIGURES:
Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2011 – 2012
Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018
Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2012
Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2013 – 2016
Figure 3 3: Global – Pegintron Sales (Million US$), 2009 – 2012
Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2013 – 2016
Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2012
Figure 3 6: Global – Forecast for Incivek Sales (Million US$), 2013 – 2016
Figure 3 7: Global – Victrelis Sales (Million US$), 2011 – 2012
Figure 3 8: Global – Forecast for Victrelis Sales (Million US$), 2013 – 2016
Figure 7 1: Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018
Figure 7 2: Global – Forecast for Faldaprevir (BI-201335) Sales (Million US$), 2014 – 2018
Figure 7 3: Global – Forecast for Asunaprevir (BMS-650032) Sales (Million US$), 2015 – 2019
Figure 7 4: Global – Forecast for Sofosbuvir (PSI-7977 or GS-7977) Sales (Million US$), 2014 – 2018
Figure 7 5: Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2015 – 2018
Figure 7 6: Global – Forecast for ABT-450/r Sales (Million US$), 2016 – 2019
Figure 7 7: Global – Forecast for ABT-072/333 Sales (Million US$), 2015 – 2019
Figure 7 8: Global – Forecast for Alisporivir Sales (Million US$), 2014 – 2019
Figure 7 9: Global – Forecast for Meracitabine (RG-7128) Sales (Million US$), 2015 – 2018
Figure 7 10: Global – Forecast for Danoprevir Sales (Million US$), 2015 – 2018
Figure 7 11: Global – Forecast for GS-9256 Sales (Million US$), 2015 – 2019
Figure 7 12: Global – Forecast for Setrobuvir (ANA-598) Sales (Million US$), 2015 – 2018
Figure 7 13: Global – Forecast for VX-222 Sales (Million US$), 2016 – 2018
Figure 7 14: Global – Forecast for GS-9190 Sales (Million US$), 2015 – 2019
Figure 7 15: Global – Forecast for BMS-791325 Sales (Million US$), 2015 – 2019
Figure 2 1: Global – Hepatitis C Drug Market (Million US$), 2011 – 2012
Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US$), 2013 – 2018
Figure 3 1: Global – Pegasys Sales (Million US$), 2005 – 2012
Figure 3 2: Global – Forecast for Pegasys Sales (Million US$), 2013 – 2016
Figure 3 3: Global – Pegintron Sales (Million US$), 2009 – 2012
Figure 3 4: Global – Forecast for Pegintron Sales (Million US$), 2013 – 2016
Figure 3 5: Global – Incivek Sales (Million US$), 2011 – 2012
Figure 3 6: Global – Forecast for Incivek Sales (Million US$), 2013 – 2016
Figure 3 7: Global – Victrelis Sales (Million US$), 2011 – 2012
Figure 3 8: Global – Forecast for Victrelis Sales (Million US$), 2013 – 2016
Figure 7 1: Global – Forecast for Simeprevir (TMC 435) Sales (Million US$), 2014 – 2018
Figure 7 2: Global – Forecast for Faldaprevir (BI-201335) Sales (Million US$), 2014 – 2018
Figure 7 3: Global – Forecast for Asunaprevir (BMS-650032) Sales (Million US$), 2015 – 2019
Figure 7 4: Global – Forecast for Sofosbuvir (PSI-7977 or GS-7977) Sales (Million US$), 2014 – 2018
Figure 7 5: Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US$), 2015 – 2018
Figure 7 6: Global – Forecast for ABT-450/r Sales (Million US$), 2016 – 2019
Figure 7 7: Global – Forecast for ABT-072/333 Sales (Million US$), 2015 – 2019
Figure 7 8: Global – Forecast for Alisporivir Sales (Million US$), 2014 – 2019
Figure 7 9: Global – Forecast for Meracitabine (RG-7128) Sales (Million US$), 2015 – 2018
Figure 7 10: Global – Forecast for Danoprevir Sales (Million US$), 2015 – 2018
Figure 7 11: Global – Forecast for GS-9256 Sales (Million US$), 2015 – 2019
Figure 7 12: Global – Forecast for Setrobuvir (ANA-598) Sales (Million US$), 2015 – 2018
Figure 7 13: Global – Forecast for VX-222 Sales (Million US$), 2016 – 2018
Figure 7 14: Global – Forecast for GS-9190 Sales (Million US$), 2015 – 2019
Figure 7 15: Global – Forecast for BMS-791325 Sales (Million US$), 2015 – 2019
LIST OF TABLES:
Table 4 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
Table 5 1: Clinical Trial – ABT-450/r
Table 4 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012
Table 5 1: Clinical Trial – ABT-450/r
